News
GSK’s Blenrep faces setback as FDA cancer committee votes against approval
Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK’s Blenrep (belantamab mafodotin) just days before the drug’s Prescription Drug User Fee Act (PDUFA) date. This marks a significant setback for the UK-based pharma company,
The anemia treatment missed its main goal in a myelofibrosis study. Meanwhile, Blenrep's return to the U.S. market may have ...
The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...
In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...
The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...
The panel expressed concerns about the proposed doses of Blenrep (belantamab mafodotin) in GSK's marketing application, ...
6hon MSN
Find insight on GSK, Novartis , Sarepta Therapeutics and more in the latest Market Talks covering Health Care.
A setback for GSK after one of its late-stage pipeline assets failed to win the support of a US panel today triggered a 6% ...
Asianet Newsable on MSN12h
GSK’s Blenrep Underwhelms FDA Panel Over Dose Risk-Benefit Balance In Myeloma; Retail Traders Stay OptimisticThe median progression-free survival was 32.6 months on the Blenrep combo compared to 12.5 months on the alternative. While ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback